Table 1.
Investments in respiratory infectious disease by sum, number of studies and with associated measures of burden
| Disease | Number of studies | Percentage of respiratory study number | Total funding | Percentage of respiratory funding | Global DALYs (2004) | Global DALYs (2010) | Mean award, £ (SD) | Median award, £ (IQR) | Top funder, millions (%) |
|---|---|---|---|---|---|---|---|---|---|
| Respiratory | 1010 | N/a | £378 975 715 | N/a | 97 786 126 | 115 227 000 | 375 224 (703 285) | 169 536 (48 568–366 068) | Wellcome, 126.9 (33.5) |
| Tuberculosis | 329 | 27.6 | £155 315 407 | 37.1 | 34 216 721 | 49 396 000 | 472 083 (930 157) | 190 467 (69 899–421 991) | Wellcome, 62.7 (40.3) |
| Influenza | 141 | 11.8 | £80 062 988 | 19.1 | – | 19 244 000 | 567 823 (818 009) | 299 988 (159 841–656 509) | MRC, 42.4 (53.0) |
| Pneumonia* | 102 | 8.6 | £27 788 770 | 6.6 | – | 48 221 000 | 272 438 (434 467) | 132 729 (44 892–281 020) | Wellcome, 12.6 (45.4) |
| Respiratory syncytial virus | 45 | 3.8 | £16 899 738 | 4.0 | – | 20 472 000 | 375 550 (480 714) | 184 292 (56 431–498 006) | Wellcome, 7.6 (44.8) |
| Chronic respiratory | 57 | 4.8 | £8 872 991 | 2.1 | – | – | 155 667 (234 736) | 65 516 (27 845–204 925) | MRC, 3.0 (33.8) |
| Pseudomonas | 43 | 3.6 | £6 473 237 | 1.5 | – | – | 150 540 (175 911) | 81 793 (11 204–253 337) | BBSRC, 4.8 (74.0) |
| Measles | 12 | 1.0 | £4 994 150 | 1.2 | 14 852 775 | 10 420 000 | 416 179 (403 740) | 284 882 (67 471–683 714) | MRC, 2.5 (49.2) |
| Aspergillus | 26 | 2.2 | £4 853 858 | 1.2 | – | – | 186 687 (420 903) | 47 948 (19 703–157 829) | NIH, 1.6 (33.1) |
| Anthrax | 9 | 0.8 | £4 624 795 | 1.1 | – | – | 513 866 (802 762) | 325 815 (140 778–398 854) | NIH, 2.5 (55) |
| Varicella | 20 | 1.7 | £4 186 582 | 1.0 | – | 581 000 | 209 329 (261 063) | 145 505 (46 117–227 502) | MRC, 1.9 (45.9) |
| Pertussis | 9 | 0.8 | £2 432 158 | 0.6 | 9 881 667 | 7 018 000 | 270 240 (246 165) | 299 840 (37 151–452 939) | Wellcome, 1.1 (46.8) |
| Coronavirus | 6 | 0.5 | £1 775 494 | 0.4 | – | – | 295 916 (281 214) | 205 076 (130 746–377 839) | Wellcome, 0.9 (55.6) |
| Mumps | 3 | 0.3 | £1 240 019 | 0.3 | – | – | 413 339 (132 436) | 471 020 (n/a) | Wellcome, 0.5 (40.1) |
| Rubella | 1 | 0.1 | £261 846 | 0.1 | – | – | 261 846 (n/a) | 261 846 (n/a) | Department of Health, 0.3 (100) |
| Diphtheria | 2 | 0.2 | £139 863 | 0.03 | 173 575 | 236 000 | 69 931 (68 317) | 69 931 (n/a) | European Commission, 0.1 (84.5) |
*Pneumonia 2010 DALY estimate includes pneumococcal pneumonia and H. influenzae pneumonia, as defined in the Global Burden of Disease 2010 study.
DALYs, disability-adjusted life years; N/a, not applicable.